ClinicalTrials.gg
RecruitingNCT03222895TIGERUpdated Feb 13, 2024

Distribution of Lymph Node Metastases in Esophageal Carcinoma

An observational study in Esophageal Neoplasms and Lymph Node Metastases, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 19 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2019; still recruiting 7 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Esophageal Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — 5 open to participants now, 6 under way, 1 of them phase 3. Esophageal Neoplasms · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Started
2019
with 1 other
Observational
3 of 17
2 open now
Registered
10th of 17
by date

Among the 17 studies in Esophageal Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), this one is one of 2 that started in 2019, is one of 3 observational ones, and was the 10th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

5 of the 17 studies in Esophageal Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Esophageal Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), or all of them as a file.
02

Study summary

Background: Lymph node status is an important prognostic parameter in esophageal carcinoma and an independent predictor of survival. Distribution of metastatic lymph nodes may vary with tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy. Surgical strategy depends on the distribution pattern of nodal metastases but consensus on the extent of lymphadenectomy differs worldwide. Especially for adenocarcinoma the distribution of lymph node metastases has not yet been described in large series. Aim of the present study is to evaluate the distribution of lymph node metastases in esophageal carcinoma specimens following transthoracic esophagectomy with at least a 2-field lymphadenectomy.

Methods: The TIGER-study is a multinational observational cohort study. All patients with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed in participating centers will be included. All lymph node stations will be excised and separately sent for pathological examination. Cluster analysis will be performed to identify patterns of metastases in relation to tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy.

Conclusion: TIGER will provide a roadmap of the location of lymph node metastases in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and survival. Patient-tailored treatment can be developed on the basis of these results, such as the the optimal radiation field and extent of lymphadenectomy based on the primary tumor characteristics.

Read the detailed description

Primary Objective:

Aim of the TIGER study is to evaluate the distribution of lymph node metastases in esophageal carcinoma specimens following transthoracic esophagectomy with at least 2-field lymphadenectomy.

Secondary Objective(s):

  • Accuracy of preoperative diagnostics (especially EUS and PET-CT) and added value of EBUS (endobronchial ultrasonography) to existing staging with EUS (endoscopic ultrasonography)/PET-CT
  • Prognostic value of different lymph node stations
  • Three- and 5-year overall and disease free survival
  • Distribution pattern of recurrence or metastases
  • Number of harvested lymph nodes in patients who are treated with and without neo-adjuvant chemoradiotherapy
  • Frequency of skip nodal metastases
  • Ratio of nodal metastases inside and outside the radiation field o Lymph node metastases will be defined as inside or outside the radiation field nodes.

Study design:

TIGER is a multinational observational cohort study. The duration of the study will approximately be 7 years (2 years inclusion, 5 years follow-up). The participating centers are distributed over 18 countries.

Sample size calculation:

In 2012, the incidence of esophageal cancer was 456,000 new cases worldwide. Only a small percentage of patients with esophageal cancer present with curable disease at time of diagnosis. We aim to include all patients with resectable disease in participating centers in a 2 year time period. We aim to include 5000 patients. This number suffices for (i) descriptive purposes and (ii) clustering of metastases diffusion profiles into meaningful subgroups within predefined strata (patients with adenocarcinoma or squamous cell carcinoma, with and without neoadjuvant therapy, different tumor heights and invasion depths, and following a 2- or 3-field lymphadenectomy).

Study procedures:

Patients will not undergo any additional procedures for the study. This is an observational study only. Patients will be treated according to national guidelines.

Follow-up:

Patients will be followed up for 5 years after the operation according to national guidelines. Follow-up will be scheduled every three months the first year, every six months the second until the fourth year and once yearly until the fifth year. Investigations are performed according to national guidelines. In the Netherlands, these are performed on indication of patients' complaints.

Statistical analysis:

Primary study parameter(s):

Numbers and percentages of resected lymph nodes and lymph node metastases will be given per lymph node station. Tumor location and invasion depth will be categorized. Patients with adenocarcinoma and squamous cell carcinoma and patients with and without neoadjuvant therapy will be analyzed separately. Also patients following a 2- or 3-field lymphadenectomy will be analyzed separately.

Secondary study parameter(s) :

The sensitivity, specificity, and positive and negative predictive values of EUS and PET-CT will be reported. Perioperative morbidity and mortality will be summarized descriptively. For each patient group mentioned in 5.4, explorative cluster analyses will be done to identify subgroups of patients with different patterns of lymph nodes metastases, tumor locations and invasion depths. Potentially relevant other characteristics at the time of surgery like age, gender, tumor differentiation, vaso-invasive growth will be included in the analysis. No restrictions will be applied to the number of clusters in each analysis, but the ratio of the largest cluster size to the smallest cluster size should preferably not exceed the value of 3 and/or the smallest cluster size should be minimally 30 patients. Characteristics introducing patient outliers will be excluded and one should further be able to attribute meaning to the resulting cluster profiles. Clusters that show the phenomenon of skip metastases will be noted. The resulting clusters will be evaluated for the diffusion pattern of future metastases during follow-up (descriptive analysis), the number of future metastases during follow-up (Poisson regression or generalized estimation equation, whichever appropriate), for 3- and 5-year overall and disease free survival (Kaplan-Meier survival analysis). Multivariate analysis will be performed using the Cox hazard regression method. The univariate analysis, including all baseline parameters, will serve as the basis for the multivariate Cox hazard regression model. Variables showing association (p \< 0.10) with survival in univariate analysis will be included in the multivariate analysis. Age and sex will be included in all multivariate analyses. Results are presented as hazard ratio with exact 95% confidence interval (95% CI). After 5-years of follow-up the efficacy index will be determined (incidence of metastases to an area (%) x 5-year overall survival rate (%)). A log-rank test, Mann-Whitney U test, or χ2-test will be used as indicated to compare groups. A value of p \< 0.05 will be considered statistically significant. Statistical analysis will be performed with SPSS 21.0 software (SPSS, Inc., Chicago, IL, USA). No formal power analysis or sample size calculation will be performed, but the 5,000 inclusions will suffice for an exploratory study.

Other study parameters:

Baseline characteristics will be presented in a baseline table. Clinical and pathology data will be presented in separate tables.

Study population:

Central data management is organized via the secured TIGER database that can be found on TIGERstudy.net. Patient inclusion and data registration of these patients will be done by the participating local PI, surgeon or fellow for the center they are representing on the TIGER website. The local PI is responsible for the inclusion and data registration of all eligible patients in his or her center.

All patients with resectable esophageal carcinoma undergoing transthoracic esophageal resection are eligible for inclusion.

Patients will be treated according to national guidelines and may be neo-adjuvantly treated with chemotherapy or chemoradiation. An esophagectomy with a 2- or 3-stage lymphadenectomy will be performed followed by a gastric tube or colonic interposition for reconstruction. All lymph node stations will be excised and separately sent for pathological examination. Initial microscopic evaluation will be performed by standard H\&E staining. In case of suspicion of micro-metastasis or isolated tumor cells in the lymph node, or in case of suspicion of residual tumor cells in patients with extensive response to neoadjuvant therapy, additional keratin stains will be performed. For the TIGER-study a new lymph node classification is designed, and lymph nodes will be recorded according to that classification system. Patients will be followed-up for 5 years after the operation.

03

Conditions studied

  • Esophageal Neoplasms
  • Lymph Node Metastases

Keywords

  • Esophageal Neoplasms
  • Lymph node metastases
  • Esophagectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with esophageal cancer who will undergo a transthoracic esophagectomy with a 2- or 3 field lymphadenectomy for esophageal cancer in one of the participating centers during the inclusion period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary squamous cell or adenocarcinoma of the esophagus or esophago-gastric junction
  • Surgically resectable (cT1-4a, N0-3, M0)
  • Adequate physical condition to undergo transthoracic surgery (ASA 1-3)
  • Transthoracic esophagectomy

Exclusion criteria

Exclusion Criteria:

  • Previous thoracic or abdominal (upper GI) surgery disturbing lymph drainage of the esophagus and stomach
  • Patients with in situ carcinoma or high grade dysplasia
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • TIGER study cohort

    This is the entire patient cohort. Alle patients with resectable esophageal cancer undergoing a transthoracic esophagectomy with at least a 2-field lymphadenectomy

06

What researchers measure

Primary outcomes

  1. Distribution of lymph node metastases

    The distribution of lymph node metastases in esophageal and esophago-gastric junction carcinoma specimens following transthoracic esophagectomy with at least 2-field lymphadenectomy in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and (disease free) survival.

    Time frame: 2 years

Secondary outcomes

  1. Accuracy of preoperative diagnostics

    Accuracy of preoperative diagnostics (especially EUS and PET-CT) and added value of EBUS to existing staging with EUS/PET-CT

    Time frame: 2 years

  2. Prognostic value of different lymph node stations

    Prognostic value of different lymph node stations

    Time frame: 2 years

  3. Distribution pattern of recurrence or metastases

    Distribution pattern of recurrence or metastases, In-field- or out-field nodal recurrence in case of neo-adjuvant chemoradiation

    Time frame: 2 years

  4. Number of harvested lymph nodes in patients who are treated with and without neo-adjuvant chemoradiotherapy

    Number of harvested lymph nodes in patients who are treated with and without neo-adjuvant chemoradiotherapy

    Time frame: 2 years

  5. Skip nodal metastases

    Analysis of the phenomenon skip nodal metastases

    Time frame: 2 years

  6. Ratio of nodal metastases inside and outside the radiation field

    Ratio of nodal metastases inside and outside the radiation field

    Time frame: 2 years

  7. 3- and 5-year overall and disease free survival

    3- and 5-year overall and disease free survival in relation to the lymph node distribution pattern

    Time frame: 7 years

07

Study locations

19 of 19 sites recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • W.L. Hofstetter, MD, PhD · Contact
  • Instituto Nacional de Câncer
    Rio De Janeiro, Brazil
    Recruiting
    • C.E. Pinto, MD, PhD · Contact
  • University of Toronto
    Toronto, Canada
    Recruiting
    • Gail Darling, MD PhD · Contact
  • Fudan University Shanghai Cancer Center
    Shanghai, Yangpu 200032, China
    Recruiting
    • H. Chen, MD, PhD · Contact
  • Hospital District of Helsinki and Uusimaa
    Helsinki, 000260, Finland
    Recruiting
    • J. Räsänen, MD, PhD · Contact
  • University Medical Center of the Johannes Gutenberg University
    Mainz, 55131, Germany
    Recruiting
    • P. Grimminger, MD, PhD · Contact
  • University of Athens, School of Medicine
    Athens, 11527, Greece
    Recruiting
    • D. Theodorou, MD, PhD · Contact
  • University of Hong Kong
    Hong Kong, 102, Hong Kong
    Recruiting
    • S.Y.K Law, MD, PhD · Contact
  • Tata Memorial Centre
    Mumbai, India
    Recruiting
    • C.S. Pramesh, MD, PhD · Contact
  • IRCCS Policlinico San Donato
    Milan, 20097, Italy
    Recruiting
    • L. Bonavina, MD, PhD · Contact
  • Ospedale San Raffaele
    Milan, Italy
    Recruiting
    • Riccardo Rosati, MD · Contact
  • University of Verona
    Verona, 37129, Italy
    Recruiting
    • G. de Manzoni, MD, PhD · Contact
  • Uonuma Institute and Niigata University
    Niigata, 9502292, Japan
    Recruiting
    • S. Kosugi, MD, PhD · Contact
  • Keio University School of Medicine
    Tokyo, 1088345, Japan
    Recruiting
    • Y. Kitagawa, MD, PhD · Contact
  • The Cancer Institute Hospital of JFCR
    Tokyo, 1358550, Japan
    Recruiting
    • M. Watanabe, MD, PhD · Contact
  • Ziekenhuisgroep Twente, Almelo & Hengelo
    Almelo, Netherlands
    Recruiting
    • E. Kouwenhoven, MD, PhD · Contact
  • Amsterdam UMC
    Amsterdam, Netherlands
    Recruiting
    • Suzanne S Gisbertz, MD PhD · Contact
  • Hospital Universitario del Mar
    Barcelona, 08003, Spain
    Recruiting
    • M. Pera, MD, PhD · Contact
  • Karolinska Institutet
    Stockholm, 17177, Sweden
    Recruiting
    • M. Nilsson, MD, PhD · Contact
08

References and documents

Publications

  • Hagens ERC, van Berge Henegouwen MI, van Sandick JW, Cuesta MA, van der Peet DL, Heisterkamp J, Nieuwenhuijzen GAP, Rosman C, Scheepers JJG, Sosef MN, van Hillegersberg R, Lagarde SM, Nilsson M, Rasanen J, Nafteux P, Pattyn P, Holscher AH, Schroder W, Schneider PM, Mariette C, Castoro C, Bonavina L, Rosati R, de Manzoni G, Mattioli S, Garcia JR, Pera M, Griffin M, Wilkerson P, Chaudry MA, Sgromo B, Tucker O, Cheong E, Moorthy K, Walsh TN, Reynolds J, Tachimori Y, Inoue H, Matsubara H, Kosugi SI, Chen H, Law SYK, Pramesh CS, Puntambekar SP, Murthy S, Linden P, Hofstetter WL, Kuppusamy MK, Shen KR, Darling GE, Sabino FD, Grimminger PP, Meijer SL, Bergman JJGHM, Hulshof MCCM, van Laarhoven HWM, Mearadji B, Bennink RJ, Annema JT, Dijkgraaf MGW, Gisbertz SS. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. BMC Cancer. 2019 Jul 4;19(1):662. doi: 10.1186/s12885-019-5761-7. PubMed 31272485 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Jan 2025, 70 months after the start.

Of 152 non-industry observational studies under Esophageal Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 252. This study's planned 70 months is below that.

Counting every sponsor, half of 174 studies reached it within 64 months; a quarter within 33 and three quarters within 252.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2017
First posted
Jul 19, 2017
StartActual
Mar 1, 2019
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jun 1, 2028
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03222895
Responsible party
S.S. Gisbertz (Upper GI Surgeon, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Jul 19, 2017
Start date
Mar 1, 2019
Primary completion
Jan 1, 2025 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Feb 13, 2024

Study contacts

Suzanne S Gisbertz, MD, PhD
Contact
s.s.gisbertz@amc.nl
+31205669111
Eliza RC Hagens, BSc
Contact
e.r.hagens@amc.uva.nl
+31205669111
Suzanne S Gisbertz, MD, PhD
study chair · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Mark I van Berge Henegouwen, MD, PHD
principal investigator · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Eliza RC Hagens, MD
study director · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion